ERBB2 and breast cancer: The combined use of adjuvant chemotherapy and trastuzumab carries a significant risk of side-effects, which should be borne in mind in patients with ER-positive/HER2-positive early-stage breast cancer that may derive minimal benefit from more aggressive therapy.